{"entity":{"id":"caris-mi-profile","kind":"drug","name":"MI Profile","aka":["Caris MI Profile"],"tldr":"Caris Life Sciences' tissue test that reads every gene's DNA and RNA and stains for tumour proteins, offered outside the United States and Europe.","summary":"MI Profile is Caris Life Sciences' tissue profiling test for solid tumours. It combines whole-exome and whole-transcriptome sequencing of more than 23,000 genes with immunohistochemistry for more than 25 tumour proteins, and reports single-nucleotide variants, insertions and deletions, copy number changes, microsatellite instability and tumour mutational burden. Two AI signatures are added for particular cases: Caris GPSai for cancer of unknown primary and Caris FOLFIRSTai for metastatic colorectal cancer. Caris gives an average turnaround of 6 to 9 days from receipt of the sample. Caris states that MI Profile is available globally excluding the United States, the European Economic Area, the EU and Switzerland; its FDA-approved tissue test in the United States is MI Cancer Seek.","status":"established","asOf":"2026-11-03","links":[{"label":"Caris Life Sciences: MI Profile","url":"https://www.carislifesciences.com/physicians/physician-tests/mi-profile/"}],"tags":["test"],"related":["caris-mi-cancer-seek","pd-l1-cps","her2-ihc-3-plus","hrd-positive","braf-fusion","ntrk-fusion","nrg1-fusion","met-ex14","met-amplification-readout","fgfr2-fusion-rearrangement","fgfr3-alteration","pdgfra-exon-18-d842v","pten-alteration","tp53-del17p","mycn-amp","mgmt-promoter-methylation","1p19q-codeletion-readout","h3-k27m"],"cancers":["metastatic-cancer"],"sections":[],"technologies":["cgp","wes-wgs","rna-seq"],"targets":[],"drugs":[],"companies":["caris"],"institutions":[],"pathways":[],"terms":["ngs","ihc","tmb","msi"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: the report lists alterations linked to approved drugs, signatures that bear on immunotherapy, and matching trials; Caris attaches a trial-matching service to every report."],"brand":"MI Profile","modality":"Tumour profiling test (whole exome, whole transcriptome and immunohistochemistry)","mechanism":"Whole-exome DNA and whole-transcriptome RNA sequencing of more than 23,000 genes from formalin-fixed tumour tissue, with immunohistochemistry for more than 25 tumour proteins and, for some tumour types, chromogenic in situ hybridisation, pyrosequencing and AI-based signatures.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/caris-mi-profile/","neighbours":{"drug":[{"id":"caris-mi-cancer-seek","kind":"drug","name":"MI Cancer Seek","route":"/drugs/caris-mi-cancer-seek/"}],"biomarker":[{"id":"1p19q-codeletion-readout","kind":"biomarker","name":"1p/19q codeletion","route":"/biomarkers/1p19q-codeletion-readout/"},{"id":"braf-fusion","kind":"biomarker","name":"BRAF fusion or rearrangement","route":"/biomarkers/braf-fusion/"},{"id":"fgfr2-fusion-rearrangement","kind":"biomarker","name":"FGFR2 fusion or rearrangement","route":"/biomarkers/fgfr2-fusion-rearrangement/"},{"id":"fgfr3-alteration","kind":"biomarker","name":"FGFR3 alteration (mutation or fusion)","route":"/biomarkers/fgfr3-alteration/"},{"id":"h3-k27m","kind":"biomarker","name":"H3 K27M mutation","route":"/biomarkers/h3-k27m/"},{"id":"her2-ihc-3-plus","kind":"biomarker","name":"HER2 IHC 3+ (HER2-positive by immunohistochemistry)","route":"/biomarkers/her2-ihc-3-plus/"},{"id":"hrd-positive","kind":"biomarker","name":"HRD-positive (genomic instability score)","route":"/biomarkers/hrd-positive/"},{"id":"met-amplification-readout","kind":"biomarker","name":"MET amplification (gene copy number)","route":"/biomarkers/met-amplification-readout/"},{"id":"met-ex14","kind":"biomarker","name":"MET exon 14 skipping mutation","route":"/biomarkers/met-ex14/"},{"id":"mgmt-promoter-methylation","kind":"biomarker","name":"MGMT promoter methylation","route":"/biomarkers/mgmt-promoter-methylation/"},{"id":"mycn-amp","kind":"biomarker","name":"MYCN amplification","route":"/biomarkers/mycn-amp/"},{"id":"nrg1-fusion","kind":"biomarker","name":"NRG1 gene fusion","route":"/biomarkers/nrg1-fusion/"},{"id":"ntrk-fusion","kind":"biomarker","name":"NTRK1/2/3 gene fusion","route":"/biomarkers/ntrk-fusion/"},{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/"},{"id":"pdgfra-exon-18-d842v","kind":"biomarker","name":"PDGFRA exon 18 mutation (D842V)","route":"/biomarkers/pdgfra-exon-18-d842v/"},{"id":"pten-alteration","kind":"biomarker","name":"PTEN alteration (sequencing) and PTEN loss (IHC)","route":"/biomarkers/pten-alteration/"},{"id":"tp53-del17p","kind":"biomarker","name":"TP53 mutation and del(17p)","route":"/biomarkers/tp53-del17p/"}],"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"caris","kind":"company","name":"Caris Life Sciences","route":"/companies/caris/"}],"term":[{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"},{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/"}]}}